Mentor Capital, Inc. (MNTR) announced that it has acquired the international patent for the smokeless administration of THC, CBD and Cannabinoids, from its developer R.L. Larson through Larson Capital, LLC.
The international formulation patent specifies the administration by vaporizer of THC from 31.5% to 92.5%, of cannabidiol (CBD) from .01% to 15%, and cannabinoids from trace to 15%. Mentor Capital is aggressively pursuing the registration of this patent through the foreign Patent Coordination Treaty (PCT) across those of the participating 148 nations where there would be a current or future marijuana extract vaporization interest. The company reports it will work with US residents with established foreign networks interested in acquiring their own national exclusive license in their native country overseas. Also, larger vape cartridge or refill suppliers with an international ambition may be interested in contacting the company for early favorable status.
“We started this patent related effort in 2012, before the cannabis boom, with an eye toward easier more discrete use by cancer patients and the elderly,” says R.L. Larson. “As an inventor and cancer survivor with long public company leadership experience, and now as a Mentor shareholder, I am pleased to be working with Mentor Capital because of their medical bias in the cannabis space and solid approach to public company operation.”
About Mentor Capital: The Company seeks to come alongside and assist larger private medical marijuana and cannabis companies and their founders in meeting their operating, liquidity and financial objectives, to add protection for investors and to help incubate private cannabis companies.
This press release is neither an offer to sell, nor a solicitation of offers to purchase, securities.
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the federal securities laws, including statements concerning financial projections, financing activities, corporate combinations, product development activities and sales and licensing activities. Such forward-looking statements are not guarantees of future results or performance, are sometimes identified by words of condition such as “should,” “could,” “expects,” “may,” “intends,” “seeks,” “looks,” “moves,” or “plans” and are subject to a number of risks and uncertainties, known and unknown, that could cause actual results to differ materially from those intended or anticipated. Such risks include, without limitation: nonperformance of investments, partner and portfolio difficulties, potential delays in marketing and sales, problems securing the necessary financing to continue operations, problems involving continued illegality of cannabis products, potential of competitive products, services, and technologies, difficulties experienced in product development, in recruiting knowledgeable personnel and in protecting patents and intellectual property. Further information concerning these and other risks is included in the Company’s most recent 10-K filings the year ended December 31, 2015, which, along with other very important information about the Company, can be found filed with the SEC and here:
The Company undertakes no obligation to update or revise such forward-looking statements to reflect new information, events or circumstances occurring after the date of this press release.